MDGL
Price
$299.57
Change
+$0.74 (+0.25%)
Updated
May 8 closing price
Capitalization
6.65B
89 days until earnings call
MRKR
Price
$1.27
Change
+$0.16 (+14.41%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
13.71M
Ad is loading...

MDGL vs MRKR

Header iconMDGL vs MRKR Comparison
Open Charts MDGL vs MRKRBanner chart's image
Madrigal Pharmaceuticals
Price$299.57
Change+$0.74 (+0.25%)
Volume$361.01K
Capitalization6.65B
Marker Therapeutics
Price$1.27
Change+$0.16 (+14.41%)
Volume$2.8K
Capitalization13.71M
MDGL vs MRKR Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. MRKR commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and MRKR is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (MDGL: $299.57 vs. MRKR: $1.28)
Brand notoriety: MDGL and MRKR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 98% vs. MRKR: 49%
Market capitalization -- MDGL: $6.65B vs. MRKR: $13.71M
MDGL [@Biotechnology] is valued at $6.65B. MRKR’s [@Biotechnology] market capitalization is $13.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileMRKR’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • MRKR’s FA Score: 1 green, 4 red.
According to our system of comparison, both MDGL and MRKR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 2 TA indicator(s) are bullish while MRKR’s TA Score has 6 bullish TA indicator(s).

  • MDGL’s TA Score: 2 bullish, 7 bearish.
  • MRKR’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, MRKR is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а -8.58% price change this week, while MRKR (@Biotechnology) price change was +7.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

MRKR is expected to report earnings on Mar 31, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.65B) has a higher market cap than MRKR($13.7M). MDGL YTD gains are higher at: -2.917 vs. MRKR (-64.309). MRKR has higher annual earnings (EBITDA): -10.19M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. MRKR (9M). MRKR has less debt than MDGL: MRKR (0) vs MDGL (120M). MDGL has higher revenues than MRKR: MDGL (180M) vs MRKR (0).
MDGLMRKRMDGL / MRKR
Capitalization6.65B13.7M48,547%
EBITDA-450.12M-10.19M4,415%
Gain YTD-2.917-64.3095%
P/E RatioN/AN/A-
Revenue180M0-
Total Cash926M9M10,289%
Total Debt120M0-
FUNDAMENTALS RATINGS
MDGL vs MRKR: Fundamental Ratings
MDGL
MRKR
OUTLOOK RATING
1..100
5675
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
33100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
5765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a45

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRKR's Valuation (17) in the Other Consumer Services industry is somewhat better than the same rating for MDGL (67) in the Pharmaceuticals Other industry. This means that MRKR’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (33) in the Pharmaceuticals Other industry is significantly better than the same rating for MRKR (100) in the Other Consumer Services industry. This means that MDGL’s stock grew significantly faster than MRKR’s over the last 12 months.

MDGL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as MRKR (94) in the Other Consumer Services industry. This means that MDGL’s stock grew similarly to MRKR’s over the last 12 months.

MDGL's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as MRKR (65) in the Other Consumer Services industry. This means that MDGL’s stock grew similarly to MRKR’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as MRKR (100) in the Other Consumer Services industry. This means that MDGL’s stock grew similarly to MRKR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLMRKR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRKR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SEAT1.760.02
+1.44%
Vivid Seats
JBTM106.251.29
+1.23%
JBT Marel Corporation
VYGR3.280.03
+0.92%
Voyager Therapeutics
NTRS97.940.77
+0.79%
Northern Trust Corp
CSCI3.50-0.28
-7.41%
COSCIENS Biopharma Inc

MRKR and

Correlation & Price change

A.I.dvisor tells us that MRKR and RCKT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRKR and RCKT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
-2.63%
RCKT - MRKR
31%
Poorly correlated
+6.18%
PMVP - MRKR
29%
Poorly correlated
+2.28%
BCYC - MRKR
29%
Poorly correlated
+5.14%
CGON - MRKR
29%
Poorly correlated
+2.95%
XNCR - MRKR
28%
Poorly correlated
-5.61%
More